The "EB virus Rta-IgG antibody test kit" of Tarcine BioMed Inc., a subsidiary of Baheal Biological Diagnosis, has successfully been recognized as a "New Technology and New Product (service) in Beijing”.

发布时间：2023-12-12 浏览次数：172次 作者：

In September 2023, the "EB virus Rta-IgG antibody detection kit (chemiluminescence immunoassay method)" independently developed by Tarcine BioMed Inc. was recognized as a "new technology and new product (service) of Beijing" by the Beijing Municipal Science and Technology Commission and other departments, and obtained the certification in December 2023.

The so called "New technologies and products (services)" refer to technologies and products launched by enterprises, universities, research institutes, and various social organizations through original innovation, integrated innovation, introduction, digestion, absorption, and re innovation. They have the characteristics of advanced technology, clear property rights, reliable quality, and broad market prospects.

The EB virus Rta-IgG antibody detection kit is based on chemiluminescence immunoassay and is used to determine the presence of EB virus Rta-IgG antibodies in human serum or plasma. This product applies exclusive patented technology and there are no similar products from other manufacturers on the domestic market, making it a truly "new" product.

The selection of the "Beijing New Technology and New Products (Services)" list is jointly reviewed, evaluated, and recognized by the Beijing Municipal Commission of Science and Technology, the Beijing Municipal Development and Reform Commission, the Beijing Municipal Bureau of Economy and Information Technology, the Beijing Municipal Commission of Housing and Urban Rural Development, the Beijing Municipal Administration for Market Regulation, and the Zhongguancun Science and Technology Park Management Committee, with high authority. Therefore, this recognition proves the strong core technological content and innovative ability of Tarcine BioMed.

In the future, Tarcine BioMed will continue to uphold the development concept of continuous innovation, focus on building enterprise innovation capabilities, improve core competitiveness, and continuously launch updated and better products.